A large new study suggests long-term use of some medications prescribed for irritable bowel syndrome (IBS) may be associated with a small but statistically significant increase in the risk of early death.
What the study found
– Researchers at Cedars‑Sinai reviewed nearly 20 years of U.S. health records for about 670,000 adults. Their analysis, published April 8 in Communications Medicine (a Nature journal), is the largest real‑world study to examine long‑term safety of IBS treatments.
– Long-term use of two opioid‑based antidiarrheal drugs — loperamide and diphenoxylate — was associated with about double the risk of death. Long-term use of antidepressants for IBS symptoms was associated with a roughly 35% higher risk of death.
– Other drug classes, including antispasmodics and treatments for constipation, were not linked to increased all‑cause mortality in this analysis.
– Investigators stressed the findings show associations, not proven cause-and-effect. The observed links may reflect higher rates of adverse events (for example, cardiovascular events, falls, and stroke) among users, or other confounding factors.
Expert perspectives
– Ali Rezaie, MD (Cedars‑Sinai), noted most IBS patients are diagnosed young and may take medications for years, while clinical trials typically last under a year. He said the results highlight an important gap in long‑term safety data and urged patients to weigh small but meaningful risks when considering prolonged treatment.
– Rudolph Bedford, MD (Providence Saint John’s), said the research shows association rather than causation and that the absolute risk to any individual is small. He emphasized that for many people the symptom relief medications provide outweighs the risks, given the potential severity of IBS symptoms and impact on quality of life.
– Ketan Thanki, MD (MemorialCare), recommended caution and further study, and suggested patients taking IBS medications discuss other risk factors with their physicians.
Context about IBS
– An estimated 25–45 million people in the U.S. have IBS. Symptom severity varies: about 31% report mild symptoms, 48% moderate, and 20% severe.
– IBS has no single known cause and is linked with multiple factors; symptoms commonly include abdominal pain, bloating, and altered bowel habits (diarrhea, constipation, or mixed patterns). Small intestinal bacterial overgrowth (SIBO) can present similarly and is sometimes misdiagnosed as IBS.
Treatment approaches and alternatives
– Medications can reduce pain and cramps, decrease diarrhea, and relieve constipation, and they remain valuable for many patients.
– Experts recommend also pursuing lifestyle and nonpharmaceutical approaches that can improve symptoms and might reduce long‑term medication needs:
– Dietary changes: trial a low‑FODMAP diet with dietitian guidance, add fiber as appropriate, reduce fats, eat smaller portions, limit caffeine and alcohol, and identify and avoid personal trigger foods.
– Regular exercise, good sleep, and stress management.
– Psychological and gut‑directed therapies such as cognitive behavioral therapy (CBT) or hypnotherapy for gut symptoms.
– Address pelvic floor dysfunction with physical therapy and biofeedback when relevant.
– Complementary approaches such as acupuncture have produced mixed results in studies.
What patients should do
– Patients currently taking long‑term IBS medications should not panic but should review their treatment with their healthcare provider, especially if they have other health risk factors.
– Discuss the expected benefits, alternative therapies, duration of use, and strategies to minimize risk (including monitoring for side effects and considering nonpharmacologic options).
– Further research is needed to clarify mechanisms behind the associations and to determine whether particular patient subgroups are at higher risk.
Bottom line
The study raises important questions about the long‑term safety of certain IBS medications, particularly some antidiarrheals and antidepressants, but the absolute risk to any one person appears small. Treatment decisions should balance symptom control and quality of life against potential long‑term risks and should be made with a clinician’s guidance.